Glen Harbor Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Glen Harbor Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$80K	Hold	1,408	–	–	﹤0.01%	1200
2019 Q2	$78K	Hold	1,408	–	–	﹤0.01%	1207
2019 Q1	$71K	Hold	1,408	–	–	﹤0.01%	1194
2018 Q4	$57K	Buy	1,408 +272	+24%	+$14K	﹤0.01%	1180
2018 Q3	$79K	Buy	1,136 +96	+9%	+$7.28K	﹤0.01%	1210
2018 Q2	$79K	Hold	1,040	–	–	﹤0.01%	1169
2018 Q1	$55K	Buy	1,040 +176	+20%	+$10.2K	﹤0.01%	1225
2017 Q4	$46K	Buy	864 +160	+23%	+$8.9K	﹤0.01%	1235
2017 Q3	$42K	Buy	704 +208	+42%	+$12.6K	﹤0.01%	1223
2017 Q2	$39K	Buy	496 +272	+121%	+$22.2K	﹤0.01%	1230
2017 Q1	$19K	Buy	+224	New	+$16.7K	﹤0.01%	1244

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Glen Harbor Capital Management's EGRX Position: Q3 2019 in Review

Glen Harbor Capital Management held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q3 2019 at 1,408 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #1200.

Glen Harbor Capital Management first reported a position in EGRX in Q1 2017 and has held it in 11 quarters since. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Glen Harbor Capital Management held 1,408 shares of Eagle Pharmaceuticals, Inc. worth $80K as of Q3 2019.
Glen Harbor Capital Management left its Eagle Pharmaceuticals, Inc. share count unchanged in Q3 2019.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1200 holding.
Glen Harbor Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2017 and has held it in 11 quarters since.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.